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Glomerular type IV collagen in patients with diabetic nephrop- (1) a disease duration of more than seven years who
athy with and without additional glomerular disease. have greater than 500 mg of proteinuria in a 24-hour
Background. Type IV collagen is a constituent of mesangial urine specimen; (2) whose urinary sediment is acellular;matrix and is increased in amount in many forms of glomerular
and (3) who have diabetic retinopathy. Renal biopsiesinjury.
Methods. We performed renal biopsies in patients who (1) are rarely performed under such clinical conditions.
were donating a kidney to a relative (LRD, N 5 6), (2) had Atypical clinical or laboratory features suggest the need
diabetic glomerulopathy with or without nephrosclerosis (DM, for a renal biopsy, and as many as one third demonstrateN 5 6), or (3) had diabetic glomerulopathy with a superim-
findings in addition to or instead of diabetic nephropathyposed glomerular lesion (DM1, N 5 5). Glomerular collagen
[1–4]. However, there is controversy as to whether non-a2(IV) and control glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) mRNAs were measured, and the former corre- diabetic glomerular lesions occur at greater than chance
lated with clinical and morphological data to assess its use- frequency in diabetic patients [5, 6]. Nevertheless, anec-
fulness in reflecting glomerular injury.
dotal reports of diabetic patients with superimposed orResults. Collagen a2(IV) mRNA levels were lowest in LRD
alternative lesions are frequently reported, albeit more(2.9 6 0.6 attomol/glomerulus), higher in DM (5.9 6 1.6, P 5
0.05), and highest in DM1 (12.7 6 2.8 attm/glomerulus, P , commonly in type 2 than type 1 diabetes [2, 7–22]. Often,
0.05 vs. LRD and vs. DM). Control GAPDH mRNA levels no clinical action is taken based on these biopsies.
were not significantly different (P . 0.05). Levels of protein-
Collagen a2(IV) mRNA and protein were chosen asuria, serum creatinine, and glomerular size did not correlate
markers of glomerular injury for this study because in-with collagen a2(IV) mRNA levels. The fractional mesangial
area and the fractional mesangial area occupied by type IV creased type IV collagen has been linked to the develop-
collagen were higher in both diabetic groups than in LRD (P , ment of glomerulosclerosis in experimental [18–27] and
1026), but the intensity of type IV collagen staining in the human [17, 28–46] diabetic and nondiabetic renal dis-diabetic patients was significantly less than that seen in the
ease. The study thus had three goals. The first was toLRD (P , 0.01). In DM1 patients, extramesangial type IV
collagen was present. Fractional mesangial area and glomerular determine whether glomerular collagen a2(IV) mRNA
collagen a2(IV) mRNA levels correlated (r 5 0.45, P , 0.05). levels and immunohistochemically identified glomerular
Conclusion. These data are consistent with a view of diabetic type IV collagen are increased in patients with diabeticnephropathy as a lesion of increased a2 type IV collagen tran-
nephropathy compared with healthy individuals. Previ-scription, increased total amount of collagen present, but de-
creased mesangial density relative to other matrix molecules. ous studies performed to examine this question in hu-
These data further demonstrate that glomerular injury super- mans used either no control tissue [39] or the tissue of
imposed on diabetic nephropathy contributes to additional patients undergoing nephrectomy for renal carcinomasstructural damage by inducing increased synthesis of type IV
[28]. Second, we wished to determine whether type IVcollagen at extramesangial sites.
collagen and its mRNA are differentially expressed in
patients with diabetic nephropathy alone compared with
patients who have both diabetic nephropathy and super-Diabetic nephropathy with or without arteriolar neph-
rosclerosis is the likely diagnosis in diabetic patients with: imposed renal lesions. A third goal was to demonstrate
that the reverse transcription-polymerase chain reaction
(RT-PCR) data obtained from glomeruli microdissectedKey words: diabetic nephropathy, type IV collagen, glomerulonephri-
tis, collagen a2(IV) mRNA. from percutaneous renal biopsies would be sufficient in
small numbers of patients per experimental group toReceived for publication October 20, 1998
yield statistically significant results, thereby validatingand in revised form October 8, 1999
Accepted for publication December 5, 1999 the usefulness of the technique for clinical purposes, and
also potentially, as a surrogate outcome in clinical trials.Ó 2000 by the International Society of Nephrology
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METHODS (GAPDH). Control samples were simultaneously run in
which the RT enzyme was omitted. Quantitative compet-Patients
itive PCR was performed using the GeneAmp DNA
Three groups of patients were studied. The first group amplification kit (Perkin Elmer Cetus Corp., Norwalk,
was comprised of living-related renal transplant donors CT, USA). In each tube containing test cDNA and am-
(LRD, N 5 6), all of whom had normal renal biopsies. plification reagents, serial dilutions of mutated template
The second group consisted of patients with diabetic cDNA were added, and the reaction mixture was ampli-
glomerulopathy (DM, N 5 6). Four of the DM patients fied. For collagen a2(IV) mRNA, PCR proceeded as
had type 1 and two had type 2 diabetes. In these, the follows: (1) 948C 3 3 minutes; (2) 42 cycles of 948C 3
glomerular lesions were characterized by thickened glo- one minute, 608C 3 one minute, and 728C 3 three min-
merular basement membranes (GBMs) and diffuse mes- utes; and (3) 728C 3 seven minutes. For GAPDH, PCR
angial expansion. Some had Kimmelstiel-Wilson nodules was done according to the manufacturer’s protocol
and/or nephrosclerosis. The third group of patients con- (Clontech, Palo Alto, CA, USA). The RT-PCR products
sisted of diabetic individuals (type 1, N 5 3; type 2, N 5 were separated by electrophoresis. The band densities
2) with additional glomerular disease (DM1, N 5 5). were analyzed by laser densitometry (Helena Labora-
All DM1 patients had at least thickened glomerular tories, Beaumont, TX, USA). The values were log trans-
basement membranes (GBMs) and some mesangial wid- formed, and a log-linear regression analysis was per-
ening, as evidence of diabetic renal disease. Some also formed against the mutant concentration for each PCR
had Kimmelstiel-Wilson nodules and nephrosclerosis. tube. The quantity of cDNA in the test sample was de-
Superimposed renal disorders were IgA nephropathy fined as that amount at which the mutant and wild-type
with or without crescents, anti-GBM disease with cres- optical density bands were equal.
cents, immune complex glomerulonephritis, and Tamm-
Horsfall protein in Bowman’s space in a patient with Primers
renal cell carcinoma but without anatomic evidence of The primers for human collagen a2(IV) were TAT
overt obstruction. For the purposes of this study, the TCC TTC CTC ATG CAC ACG GCG (sense) and CCA
presence of arteriosclerosis and/or nephrosclerosis in pa- ATT TTT GGG TTG GCA CC (antisense). Results with
tients with diabetes mellitus was not considered as an these primers and the competitive mutant have been
additional or alternative diagnosis. previously reported [28, 30]. The primers and competi-
tive mutant for human GAPDH (G3PDH) were pur-
Clinical data
chased from Clontech.
Serum creatinine, 24-hour urine protein and creati-
Morphological assessmentsnine, and hemoglobin A1c measurements (in the diabet-
ics only) were measured in the hospital clinical labora- Renal biopsy tissue was manually divided, and tissue
tory. The mean arterial pressure was calculated using was fixed in alcoholic Bouin’s solution, Zeus solution,
measurements taken during the outpatient visit prior to or glutaraldehyde for evaluation by light, immunofluo-
the renal donation or biopsy. Renal size was measured rescence, and electron microscopy in the standard fash-
by ultrasound in the diabetic patients and by intravenous ion (47, 48). Glomerular surface area was measured using
urographic measurement in transplant donors. Micrometer V1.0 software (Cell Analysis Systems, Inc.,
Oak Brook, IL, USA). Glomerular tuft volume (GTV)
Glomerular microdissection and was calculated based on the following formula: GTV 5
RT-PCR measurements 1.25 (surface area)3/2 [21]. Depending on the adequacy
Microdissection and RT-PCR measurements were of the biopsy, these measures were based on 3 to 25
performed as previously described [28, 30], with minor glomeruli per subject.
modifications. Glomeruli from the renal core were micro-
Morphometric measures of fractional mesangial areadissected at 48C in vanadyl ribonucleoside complex,
and the fractional collagen IV arearinsed, aliquotted four per tube in RNAse inhibitor, solu-
bilized in triton buffer, lyzed by freezing and thawing, Glomeruli were stained either with periodic acid me-
and reverse transcribed to cDNA using a Boehringer thenamine silver (“Jones” stain) or with monoclonal
Mannheim cDNA synthesis kit (Mannheim, Germany). mouse antihuman type IV collagen antibody (Dako, Car-
Standard PCR was performed to check the adequacy pinteria, CA, USA) by an avidin-biotin immunoperoxi-
of the RT procedure, and satisfactory samples from all dase method. Each glomerulus was photographed and
glomeruli from a given patient were pooled. cDNA from subjected to point counting by superimposing a grid over
one fifth of a glomerulus per reaction tube was used the photo montages and identifying the glomerular re-
to measure for collagen a2(IV) and one tenth of a glo- gion under the area where grid lines intersected. The
mesangial region (comprised of mesangial cells, nuclei,merulus for glyceraldehyde-3-phosphate dehydrogenase
Adler et al: Type IV collagen in diabetic nephropathy2086
and matrix as a single region) and the mesangial staining Glomerular RT-PCR measurements
for type IV collagen were quantitated by this method. Glomerular collagen a2(IV) mRNA levels were low-
Fractional mesangial area (AFM) and the fractional type est in LRD (2.9 6 0.6 attomol/glomerulus), higher in DM
IV collagen area (AFTypeIV) were calculated by dividing (5.9 6 1.6 attomol/glomerulus, P 5 0.05), and highest in
the total number of points per glomerulus for these re- DM1 (12.7 6 2.8 attomol/glomerulus, P , 0.05 LRD vs.
gions by the total number (N) of glomerular points DM1 and DM vs. DM1; Fig. 1). Glomerular GAPDH
counted and multiplying by 100. Equations 1 and 2 de- mRNA levels were not significantly different among the
scribe these calculations: groups (P 5 0.6; Fig. 2).
Morphological assessmentsAFM 5
(mesangial points per glomerulus)
(Total N glomerular tuft points)
3 100
Representative biopsies are shown in Figure 3. Biopsy
(Eq. 1) material in LRD showed normal kidney in all cases. The
DM biopsies showed a spectrum of diabetic changesAFTypeIV
ranging from mild to moderately diffuse increases in
mesangial matrix to marked nodules of mesangial matrix.5
(mesangial type IV points per glomerulus)
(Total N glomerular tuft points)
3 100
Capillary basement membranes were thickened to vary-
(Eq. 2) ing degrees. All biopsies had some degree of tubular
atrophy with interstitial fibrosis and arteriolar hyaliniza-
Immunoperoxidase staining intensity was also evaluated tion of the walls. DM1 biopsies had a broader spectrum
semiquantitatively on a scale of 0 to 41. of morphologic diabetic alterations, ranging from a very
mild, diffuse increase in mesangial matrix and mild capil-In situ hybridization for collagen IV
lary basement membrane thickening to marked mesan-
In situ hybridization was performed by the method of gial nodules and severe thickening of the basement mem-
Suzuki et al on frozen renal sections from each patient branes. Biopsies with IgA nephropathy and immune
[46]. Negative controls included pretreating the tissue complex glomerulonephritis showed mild to moderate
with RNAse after proteinase digestion, followed by pre- mesangial hypercellularity with IgA or IgM, respectively,
hybridization and hybridization. In addition, the in situ on immunofluorescence, and electron dense deposits.
procedure was carried out substituting buffer for the One biopsy with IgA deposits had 30% fresh to fibrocel-
antisense probe. Staining was evaluated on a scale of 0 lular crescents. The biopsy demonstrating anti-GBM an-
to 41. tibody nephritis had 80% fresh to fibrocellular crescents.
The single nephrectomy specimen revealed Tamm-Hors-
Statistics fall protein in glomerular urinary spaces, indicating ob-
struction or reflux. Tubular atrophy and interstitial fi-Results were analyzed using Access software and an
brosis varied from rarely present to involving one thirdExcel Spreadsheet (Microsoft, Seattle, WA, USA) and
of the renal parenchyma.the StatMost software package (DataMost Corp., Salt
Obsolescent glomeruli were rare in the LRD (1.4 6Lake City, UT, USA). The significance of analysis of
1.4% of the total number of glomeruli present, range 0variance (ANOVA) testing was ascertained using the
to 8.3% for the group) and were more common in theStudent–Neuman–Keul’s test and Student’s t-test. Pear-
DM (15.1 6 11.0% of total glomeruli, range 0 to 68.4%)son’s correlation coefficient was used to test relationships
and DM1 groups (8.4 6 3.5% of total glomeruli, rangebetween sets of data. Results are expressed as the mean 6
1.0 to 20%). Segmental sclerosis was absent in LRD (0 6SEM.
0) and was more common in the DM group (17.3 6 7.0%
of glomeruli present on biopsy, range 0 to 40%) and the
DM1 group (3.6 6 2.5% of glomeruli present on biopsy,RESULTS
range 0 to 12.5%). The GTV was larger in DM (3.27 6Clinical data
0.38 3 106 m3) and DM1 (3.88 6 0.34 3 106 m3) than in
Clinical parameters are summarized in Table 1. Renal LRD (1.40 6 0.18 3 106 m3, P , 0.05 DM and DM1 vs.
size was measured ultrasonographically in the DM LRD). Although there was more than a twofold differ-
groups and angiographically in the living related donor ence in collagen a2(IV) mRNA levels between the DM
(LRD), and thus, the values are not directly comparable. and DM1 groups, the difference between the GTV mea-
However, renal length in LRD was 11.7 6 0.73 cm. In surements between the two groups did not reach statisti-
DM patients, the renal length was 11.5 6 0.5 cm, and cal significance (P 5 0.075). A significant relationship
in DM1, it was 12.5 6 0.7 cm. Angiotensin-converting between glomerular collagen a2(IV) mRNA levels and
enzyme inhibitor use was limited to two patients, both GTV measurements in the DM and DM1 groups was
not found (r 5 0.5, P 5 0.1).in the DM group.
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Table 1. Clinical characteristics
Serum creatinine Urine protein
Group Age years HbA1c % mg/dL Uprotein/creatinine g/24 h MAP mm Hg
LRD 33.763.4 ND 0.860.04 0.0960.03 0.1260.0 87.262.0
(28–46) (0.6–0.9) (0.03–0.23) (82–95)
DM 44.065.6 8.860.6 1.460.3 5.0361.79a 4.4361.48a 102.866.1
(29–62) (7.9–10.7) (0.5–2.6) (0.52–9.04) (83–121)
DM1 40.266.4 7.561.9 2.460.8 3.661.58a 5.8462.30a 101.8614.2
(25–58) (4.0–12.7) (0.7–4.7) (2.40–12.4) (67–136)
Values expressed as mean 6 SEM. Ranges of values for each group are in parentheses. Abbreviations are: LRD, living-related transplant donor; DM, diabetic
nephropathy alone; DM1, diabetic nephropathy with superimposed lesions; Hb, hemaglobin; Uprotein/creatinine, the ratio of urinary protein divided by creatinine; MAP,
mean arterial pressure.
aP , 0.05 compared with LRD
Fig. 1. Glomerular collagen a2(IV) mRNA levels were lowest in living
Fig. 2. Glomerular GAPDH mRNA levels were not significantly dif-related transplant donor kidneys (LRD), higher in diabetic nephropathy
ferent in kidneys from patients in the LRD, DM, or DM1 groups.alone (DM), and highest in diabetic nephropathy with superimposed
lesions (DM1). aP # 0.05 vs. LRD; bP , 0.05 vs. DM.
In situ hybridization for collagen IV
Morphometric measures of fractional mesangial area Glomeruli with mild diffuse mesangial expansion con-
and the fractional collagen IV area tained mesangial cells with 1 to 21 cytoplasmic staining
for type IV collagen mRNA (Fig. 7A). As mesangialThe fractional mesangial area in LRD was 18.8 6
expansion increased, the expression of type IV collagen0.9% compared with 45.7 6 1.6% in DM patients and
was reduced, with nodules containing only rare mesan-41.2 6 0.8% in DM1 patients (P , 1026, DM and DM1
gial cells showing trace staining (Fig. 7B), similar to thatvs. LRD; Fig. 4). Similarly, the fractional mesangial area
described previously [42]. Glomeruli from DM1 patientsstaining for type IV collagen was less in LRD (18.2 6
contained mesangial cells staining appropriately for the1.3%) compared with DM (49.0 6 1.3%) and DM1
degree of diabetic involvement. In DM1 patients with-(41.5 6 6.5%, P , 1026, DM and DM1 vs. LRD). There
out crescents, there was variable focal epithelial cell cyto-was a statistically significant correlation between the glo-
plasmic 11 staining for type IV collagen mRNA. Inmerular collagen a2(IV) mRNA levels and the fractional
patients with crescentic lesions, there was extensive 31mesangial area (r 5 0.49, P 5 0.044), thus demonstrating
staining of cells within the urinary space (Fig. 7B), whilea relationship between the mRNA measure employed
adjacent glomeruli without crescents had focal 31 stain-and histologic glomerular damage (Fig. 5). A similar
ing of epithelial cells (Fig. 7C).
relationship between collagen a2(IV) mRNA and the
fractional mesangial area staining for type IV collagen
DISCUSSIONwas also appreciated (r 5 0.45, P 5 0.07). In contrast,
the intensity of type IV collagen staining was significantly This study had three major goals. The first was to clar-
stronger in LRD (4.0 6 0.0) compared with DM (2.5 6 ify the roles of classical type IV collagen mRNA and
0.3) and DM1 (2.6 6 0.6, P , 1026, DM and DM1 vs. protein as valid markers for mesangial expansion and
glomerular injury in patients with a spectrum of diabeticLRD; Fig. 6).
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Fig. 3. Representative glomeruli from patients
from the LRD, DM, and DM1 groups. (A)
Glomeruli from LRD donor biopsy. There are
normal mesangial regions and capillary walls
(periodic acid-methenamine silver stain). (B)
Type IV collagen stain shows no increase in
collagen, and the staining intensity is normal
(similar to capillary basement membranes).
(C) Glomeruli from DM. There is diabetic
glomerulosclerosis characterized by diffuse in-
crease in mesangial matrix material with re-
duced cellularity and thickened capillary base-
ment membranes (periodic acid-methenamine
silver). (D) There is increased mesangial type
IV staining with reduction of staining intensity,
more pronounced in the central mesangial re-
gions (arrowhead). (E) Glomeruli from DM
with superimposed crescentic glomerulone-
phritis. There is a background of diabetic glo-
merulosclerosis with a nodular increase in
mesangial matrix material and focal thickening
of capillary basement membranes. The urinary
space contains a fresh crescent composed of
cells and fibrin, and there are focal leukocytes
in capillary lumina (periodic acid-methena-
mine silver). (F) There is an increase in mesan-
gial area staining for type IV collagen with
central areas of reduced staining intensity.
Collagen is also evident within the fibrocellu-
lar crescent (A–F 3170).
Fig. 5. There was a weak (r 5 0.45) but statistically significant (P ,
Fig. 4. The fractional mesangial area (mesangium) and the fractional 0.05) correlation between glomerular collagen a2(IV) mRNA levels
mesangial area staining for type IV collagen (Mes collagen IV) were and morphometrically measured mesangial expansion. Symbols are:
higher in the DM (j) and DM1 ( ) groups than in LRD (h; aP , 1026). (j) LRD; (d) DM; (m) DM1 (P , 0.05; r 5 0.45).
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Fig. 6. The intensity of type IV collagen staining was higher in LRD
than in the DM or DM1 groups (P , 0.01).
nephropathy from mild to relatively histologically ad-
vanced. The second was to determine whether additional
glomerular lesions superimposed on diabetic glomerulo-
pathy were associated with an increased expression of
glomerular a2 type IV collagen mRNA and protein com-
pared with patients with DM alone. In both cases, this
study found in the affirmative, demonstrating increased
glomerular collagen a2(IV) mRNA levels in patients
with histologically apparent diabetic nephropathy and
further increments in patients with diabetic nephropathy
plus superimposed glomerular disorders, while no sig-
nificant differences were observed among groups for the
control mRNA GAPDH. Statistically significant differ-
ences in collagen a2(IV) mRNA levels were obtained
with as few as five or six patients in each clinically defined
group, confirming the third major goal, thus demonstra-
ting the usefulness of this technique in showing differ-
ences among small numbers of patients. The latter con-
firms four other published studies using human glomeruli
from patients and examining collagen a2(IV), transform- Fig. 7. In situ hybridization for type IV collagen mRNA in glomeruli
ing growth factor-b1, and matrix metalloproteinase-2 of DM and DM1 patients. (A) DM patient with mild diffuse increase
in mesangial matrix. There is 1 to 21 scattered staining of mesangialmRNAs [28, 39, 49, 50]. Our studies further demonstrated
cells (arrows). (B) DM1 patient with moderate mesangial matrix in-
a correlation between fractional mesangial expansion crease and a segmental crescent. There is 31 staining of crescentic cells
within the urinary space (arrow). (C) Glomerulus without a crescent inand collagen a2(IV) mRNA levels, underscoring the re-
DM1 crescentic patient. An epithelial cell has 31 cytoplasmic staininglationship between histologic glomerular damage and
(arrow). The underlying diabetic lesion is moderate to severe with
collagen a2(IV) mRNA levels. The immunohistochemi- nodule formation; note that there is no staining for type IV collagen
mRNA in mesangial cells within the nodules, as has been describedcal studies showed that the distribution of type IV colla-
previously.gen was increased within a widened mesangium, but was
decreased in density in diabetic nephropathy.
Comparative data to other human glomerular studies relative to a3 type IV collagen mRNA were demon-
using RT-PCR strated [28]. In the other, collagen a2(IV) mRNA was
Our data confirm and extend two previously published increased in specimens with glomerulosclerosis, indepen-
reports evaluating the expression of type IV collagen dent of the underlying histopathological diagnosis [39].
mRNA and protein in diabetic nephropathy in patients. In the former report, the increment in a2 type IV colla-
gen mRNA was expressed as a ratio relative to a a3 typeIn one, increments in glomerular a2 type IV collagen
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IV collagen mRNA [28], and in the latter as a ratio type IV collagen and its mRNA to be more abundantly
expressed, as assessed immunohistochemically in mildrelative to b-actin [39]. In one, the control specimens
were uninvolved areas of tissue from patients undergoing compared with more advanced lesions, as previously de-
scribed [40]. Taken together, these data are consistentnephrectomy for renal cancers [28]; in the other, control
tissue was not studied [39]. The current report is the first with the interpretation that in the mesangium, the mod-
erately advanced diabetic nephropathy lesion is charac-study in humans in which glomerular mRNA for a2
type IV collagen was statistically significantly elevated, terized by an increase in the transcription and translation
of a2 type IV collagen, but a decrease in quantity relativeexpressed on a per glomerulus basis, concomitant with
no demonstrable difference in a housekeeping gene, and to other matrix molecules. Furthermore, in the most
advanced lesions, there is a tendency toward lesser colla-compared with normal healthy human glomeruli.
gen expression.
Lack of effect of glomerular hypertrophy on collagen
mRNA level Increased glomerular collagen IV mRNA in patients
with DM and superimposed glomerular lesionsIt is theoretically possible that nonspecific increments
in mRNA caused by glomerular hypertrophy could oth- These results also demonstrate that glomerular colla-
gen a2 (IV) mRNA levels are higher when there areerwise confound data interpretation in diabetic glomer-
uli. Whereas collagen a2(IV) mRNA increased twofold glomerular lesions superimposed on diabetic nephropa-
thy compared with values measured in diabetic nephrop-per glomerulus in DM patients and fourfold per glomeru-
lus in the DM1 patients, GAPDH levels were similar athy alone. This was shown in patients with diabetic glom-
erulopathy and superimposed IgA nephropathy with anddespite the increased size of the diabetic glomeruli. Fur-
thermore, there was no significant relationship between without crescents, Goodpasture’s syndrome, mesangial
proliferative immune complex glomerulonephritis, orglomerular size and collagen a2(IV) mRNA levels among
the samples in this study, substantiating the indepen- obstruction from renal cell carcinoma causing Tamm-
Horsfall protein to be present in Bowman’s space. Thesedence of glomerular mRNA from glomerular size. Taken
together, these data dissociate glomerular mRNA levels findings parallel the larger increments in type IV collagen
mRNA levels seen in animal models with crescentic glo-from glomerular size in diabetes and underscore the speci-
ficity of the increment in a2 type IV collagen mRNA. merulonephritis [51], compared with the more modest
increments seen in animal models of diabetic nephropa-
Glomerular collagen IV in DM increased in amount thy [52, 53]. The higher collagen a2(IV) mRNA levels
but decreased in density, and increased early but in the DM1 group appear to be due to the recruitment
decreased in the most advanced lesions of additional cells, particularly glomerular epithelial cells
and cells comprising crescents, which contribute to theImmunohistochemical studies in diabetic humans have
been inconsistent. Early immunohistochemical studies, excess in collagen a2(IV) mRNA, as demonstrated by
in situ hybridization.as well as a few more recent studies, reported increased
type IV collagen in the expanded mesangium of biopsies Superimposition of another glomerular lesion on dia-
betic nephropathy is a well-recognized phenomenon,from patients with diabetic nephropathy, and also some-
times in Kimmelstiel-Wilson nodules [31, 32, 37, 40, 41, particularly but not exclusively in patients with type 2
diabetes [7, 8, 11–15, 17, 54]. However, there is a reti-45]. Others, using both immunohistochemical and immu-
noelectron microscopic techniques, demonstrated that cence to identify any but the most aggressive of addi-
tional glomerular lesions by renal biopsy. This is duetype IV collagen disappears or is present at a lesser
density in patients with moderate or advanced diabetic both to a reluctance to use corticosteroids in these pa-
tients and to a belief by many that the ultimate prognosisnephropathy [40, 42–44]. This is reported to be particu-
larly true for those with a more rapid course [44]. In the of these individuals will usually be determined by their
underlying diabetic renal disease. The current findingsstudies reported herein, immunoperoxidase staining for
type IV collagen confirms the finding of diminished den- demonstrate a twofold further increase in glomerular
collagen a2(IV) mRNA levels in these patients com-sity of type IV collagen in widened mesangial regions in
diabetic nephropathy. However, the overall increase in pared with those with isolated diabetic nephropathy and
suggest that superimposed renal lesions may acceleratemesangial area and the diffuse representation of type
IV collagen throughout the widened mesangial region glomerular injury at least in part by further increasing
type IV collagen synthesis at extramesangial sites.suggest an overall increase in type IV collagen in the
enlarged diabetic glomerulus. This is consistent with In summary, this study demonstrated that collagen
a2(IV) mRNA levels, the fractional mesangial area, andstudies previously reported by Zhu et al in which the
total type IV collagen per glomerulus, as assessed by the fractional area staining for type IV collagen are in-
creased in patients with diabetic nephropathy and areimmunoelectron microscopy, was increased but the den-
sity was decreased [44]. There was also a tendency for further increased in patients with superimposed glomer-
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tracellular microtubules and nodular glomerulosclerosis in a dia-ular lesions, although the density of type IV collagen in
betic patient. Pathol Res Pract 191:585–596, 1995
diabetic nephropathy is diminished. Increments in mRNA 13. Orfila C, Lepert JC, Modesto A, Pipy B, Suc JM: Henoch-Schon-
lein purpura in a patient with diabetic nephropathy. Am J Kidneyand protein reflected the presence of mesangial expan-
Dis 24:509–514, 1994sion in diabetic patients, but also the addition of extra-
14. Venkataraman TV, Knickerbocker F, Sheldon CV: Unusual
mesangial sites of collagen IV synthesis in patients with causes of renal failure in diabetics: Two case studies. J Okla State
Med Assoc 83:164–168, 1990superimposed glomerular injury. The ability of RT-PCR
15. Gans R, Ueda Y, Ito S, Kohli R, Min I, Shafi M, Brentjensto discern differences between groups with small num-
J: The occurrence of IgA-nephropathy in patients with diabetes
bers of patients in each group suggests that the technique mellitus may not be coincidental: A report of five cases. Am J
Kidney Dis 20:255–260, 1992may be valuable both in measuring surrogate outcomes
16. Furuta T, Seino J, Saito T, Sato H, Agatsuma J, Ootaka T, Satohin clinical trials and in importing additional prognostic T, Yoshinaga K: Insulin deposits in membranous nephropathy
information in the evaluation of routine renal biopsy associated with diabetes mellitus. Clin Nephrol 37:65–69, 1992
17. Gallego N, Olivares F, Mampaso F, Gonzalo A, Barrio R,material.
Estepa R, Ortuno J: Membranous nephropathy, antitubular base-
ment membrane antibodies and alveolar hemorrhage in a diabetic
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